We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands, Inc. (TLRY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Tilray Brands, Inc. (TLRY - Free Report) closed the most recent trading day at $6.32, moving -3.36% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.67%. Meanwhile, the Dow experienced a drop of 1.73%, and the technology-dominated Nasdaq saw a decrease of 2.15%.
Prior to today's trading, shares of the company had lost 18.15% lagged the Medical sector's loss of 7.36% and the S&P 500's loss of 6.15%.
The investment community will be closely monitoring the performance of Tilray Brands, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on April 1, 2026. The company is predicted to post an EPS of -$0.14, indicating a 86% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $205.93 million, up 10.85% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.48 per share and a revenue of $869.99 million, representing changes of -580% and +5.93%, respectively, from the prior year.
Any recent changes to analyst estimates for Tilray Brands, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 14.18% increase. As of now, Tilray Brands, Inc. holds a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 159, positioning it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TLRY in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Tilray Brands, Inc. (TLRY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Tilray Brands, Inc. (TLRY - Free Report) closed the most recent trading day at $6.32, moving -3.36% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.67%. Meanwhile, the Dow experienced a drop of 1.73%, and the technology-dominated Nasdaq saw a decrease of 2.15%.
Prior to today's trading, shares of the company had lost 18.15% lagged the Medical sector's loss of 7.36% and the S&P 500's loss of 6.15%.
The investment community will be closely monitoring the performance of Tilray Brands, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on April 1, 2026. The company is predicted to post an EPS of -$0.14, indicating a 86% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $205.93 million, up 10.85% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.48 per share and a revenue of $869.99 million, representing changes of -580% and +5.93%, respectively, from the prior year.
Any recent changes to analyst estimates for Tilray Brands, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 14.18% increase. As of now, Tilray Brands, Inc. holds a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 159, positioning it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TLRY in the coming trading sessions, be sure to utilize Zacks.com.